TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02970929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
Study: NCT01348737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3839
Description: Single Oral Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD3839 Placebo
Description: Single Oral Dose
Study: NCT00859755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-403, glucokinase activator; oral
Description: single dose, escalating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT01815957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rnalozine
Description: . After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
Study: NCT04409847

Intervention type: DIAGNOSTIC_TEST
Intervention: ABPM
Description: 24 hour ambulatory blood pressure monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: ABPM
Description: 24 hour ambulatory blood pressure monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: FMD
Description: Flow mediated dilatation

Intervention type: DIAGNOSTIC_TEST
Intervention: FMD
Description: Flow mediated dilatation

Intervention type: DIAGNOSTIC_TEST
Intervention: PWV
Description: Pulse wave velocity

Intervention type: DIAGNOSTIC_TEST
Intervention: PWV
Description: Pulse wave velocity

Intervention type: DIAGNOSTIC_TEST
Intervention: Rarefaction
Description: nailbed capillaroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Rarefaction
Description: nailbed capillaroscopy
Study: NCT02932267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% / BPO 2.5% gel
Description: Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
Study: NCT02029742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)
Description: CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
Study: NCT02484469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Virtual Human Project
Description: Virtual Human educational videos about leprosy
Study: NCT04876547

Intervention type: PROCEDURE
Intervention: appendectomy
Description: appendectomy performance

Intervention type: PROCEDURE
Intervention: appendectomy
Description: appendectomy performance
Study: NCT05333094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brackets
Description: Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brackets
Description: Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brackets
Description: Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)
Study: NCT00342368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP delivered by an Helmet
Description: continuous positive airway pressures delivered through an helmet
Study: NCT00885820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (Prednisone)
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (Prednisone)
Description: Oral
Study: NCT04877509

Intervention type: BIOLOGICAL
Intervention: Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization
Description: Micronutrient assays on heparinized plasma.
Study: NCT02011139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral group therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral group therapy
Study: NCT03001271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Study: NCT03202693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Study: NCT02486861

Intervention type: OTHER
Intervention: optical coherence tomography
Study: NCT03496623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil solution
Description: Treprostinil inhalation solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Placebo solution
Study: NCT01030848

Intervention type: DEVICE
Intervention: Total Knee Replacement (LCS rotating platform)
Study: NCT01616225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen (Human Growth Hormone)
Description: Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen (Human Growth Hormone)
Description: Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Saizen Control (Standard IVF Protocol)
Description: All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
Study: NCT01922765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin, clarithromycin, metronidazole, rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin, clarithromycin, metronidazole, rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin, clarithromycin, metronidazole, rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin, clarithromycin, metronidazole, rabeprazole
Study: NCT00938834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CFQ Qigong
Description: CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
Study: NCT04568785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Influenza vaccine
Description: Previous to the intervention, patients were asked about the reasons to reject the influenza vaccine. Brief Intervention was performed by the healthcare professional during the consultation. It was given verbally, with written support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal advice
Description: In the CG the influenza vaccine advice was the normal advice that professionals used to give their patients and was not asked for the reasons for the rejection of the vaccine to prevent them from influencing the advice.
Study: NCT03949179

Intervention type: DEVICE
Intervention: The Low Back Pain and Disability Drivers Management (PDDM) model
Description: The Low Back Pain and Disability Drivers Management (PDDM) model aims to identify the domains influencing pain and disability to guide clinical decisions. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers (i.e., somatic, inflammatory or mixed pain), 2) nervous system dysfunction (NSD) drivers (i.e., sensitization of the peripheral and/or central nervous system), 3) comorbidity drivers (i.e., physical and/or mental health comorbidities), 4) cognitive-emotional drivers (i.e., maladaptive cognitions and/or behaviors) and 5) contextual drivers (i.e., occupational-related and social environmental contextual drivers). This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability.
Study: NCT02495467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Description: At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Description: At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED Placebo
Description: At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED Placebo
Description: At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
Study: NCT04953832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants are asked to remember a series of items while solving puzzles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Participants are asked to remember a series of items while solving puzzles.
Study: NCT02848742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Dermal cryotherapy
Study: NCT01278732

Intervention type: OTHER
Intervention: no intervention performed
Description: no intervention is performed
Study: NCT02566239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Share activity data with care team
Description: Share participant in-home activity data with retirement community care team.
Study: NCT01704677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement
Description: The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation
Description: The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
Study: NCT02445339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Description: The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
Study: NCT00312897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: 10 wk treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: placebo comparator
Study: NCT03983057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
Study: NCT00441467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide
Description: 5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
Study: NCT05961423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic surgery
Description: The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
Study: NCT00817193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical Activity program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Wellness program
Study: NCT00135941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
Study: NCT02155465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID
Study: NCT03001271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02155465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg PO QD
Study: NCT00465270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER PFO Occluder
Description: patent foramen ovale closure device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - Medical Management
Description: Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
Study: NCT01819597

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Encephaloduroarteriosynangiosis (EDAS)
Description: The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
Study: NCT03866330

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of WJMSC
Description: ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of WJMSC
Description: ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of WJMSC
Description: ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
Study: NCT01394562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject (ferric carboxymaltose)
Description: Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
Study: NCT00492960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 900 mg gluten
Description: gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 900 mg gluten
Description: gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 900 mg gluten
Description: gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 900 mg gluten
Description: gelatin capsules
Study: NCT04202874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeon-administered transversus abdominis plane (TAP)
Description: Prior to fascial closure, the rectus muscle is gently elevated superiorly and the surgeon identifies its lateral border; the nerves that supply the anterior abdominal wall travel through the myofascial plane between internal oblique and transversus abdominis muscles, 2 fingerbreadths above the iliac crest. Access to this plane can easily be achieved by inserting a blunted needle through the parietal peritoneum; there is an appreciable loss of resistance ('one pop') and the correct plane is entered. After careful aspiration to ensure no vascular injury has occurred, 20 mL 0.25% bupivacaine or 20 mL of normal saline is injected slowly. The same procedure is repeated on the other side.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgeon-administered transversus abdominis plane (TAP)
Description: Prior to fascial closure, the rectus muscle is gently elevated superiorly and the surgeon identifies its lateral border; the nerves that supply the anterior abdominal wall travel through the myofascial plane between internal oblique and transversus abdominis muscles, 2 fingerbreadths above the iliac crest. Access to this plane can easily be achieved by inserting a blunted needle through the parietal peritoneum; there is an appreciable loss of resistance ('one pop') and the correct plane is entered. After careful aspiration to ensure no vascular injury has occurred, 20 mL 0.25% bupivacaine or 20 mL of normal saline is injected slowly. The same procedure is repeated on the other side.
Study: NCT01939717

Intervention type: OTHER
Group type: OTHER
Intervention: Dance group
Description: Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class.
Study: NCT01530243

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same as tolterodine and terazosin dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terazosine
Description: 2 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: 2 mg daily
Study: NCT03001271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo